Activation of BAD and translocation to mitochondria |
|
Activation of PKB |
|
AKT phosphorylates targets in the cytosol |
|
AKT phosphorylates targets in the nucleus |
|
AKT-mediated inactivation of FOXO1A |
|
APC truncation mutants have impaired AXIN binding |
|
AXIN missense mutants destabilize the destruction complex |
|
Beta-catenin phosphorylation cascade |
|
CD28 dependent PI3K/Akt signaling |
|
Constitutive PI3K/AKT Signaling in Cancer |
|
CRMPs in Sema3A signaling |
|
CTLA4 inhibitory signaling |
|
deactivation of the beta-catenin transactivating complex |
|
Degradation of beta-catenin by the destruction complex |
|
disassembly of the destruction complex and recruitment of AXIN to the membrane |
|
Downregulation of ERBB2:ERBB3 signaling |
|
G beta:gamma signalling through PI3Kgamma |
|
GPVI-mediated activation cascade |
|
Inhibition of TSC complex formation by PKB |
|
misspliced GSK3beta mutants stabilize beta-catenin |
|
Negative regulation of the PI3K/AKT network |
|
PDE3B signalling |
|
PIP3 activates AKT signaling |
|
Regulation of HSF1-mediated heat shock response |
|
S33 mutants of beta-catenin aren't phosphorylated |
|
S37 mutants of beta-catenin aren't phosphorylated |
|
S45 mutants of beta-catenin aren't phosphorylated |
|
T41 mutants of beta-catenin aren't phosphorylated |
|
Translocation of GLUT4 to the plasma membrane |
|
truncations of AMER1 destabilize the destruction complex |
|
VEGFR2 mediated vascular permeability |
|